www.fdanews.com/articles/87405-incyte-launches-study-of-incb13739
INCYTE LAUNCHES STUDY OF INCB13739
June 7, 2006
Incyte has initiated a Phase I clinical trial of INCB13739, an orally available small molecule inhibitor of 11beta-HSD1 (11-beta hydroxysteroid dehydrogenase type 1). 11beta-HSD1 is an enzyme that appears
to be critical to the development of Type 2 diabetes.
The trial is a
double-blind, placebo-controlled, single- and multiple-dose-rising study designed
to assess the safety and pharmacokinetics of INCB13739 in healthy volunteers.
The program will also evaluate the ability of INCB13739 to inhibit 11beta-HSD1
activity in adipose tissue and liver of high-body mass index individuals. Preclinical
studies have shown that 11beta-HSD1 activity in these two tissues may be a primary
driver of insulin resistance and diabetes.